JP2023538065A - 多発性硬化症の寛解を処置する方法 - Google Patents

多発性硬化症の寛解を処置する方法 Download PDF

Info

Publication number
JP2023538065A
JP2023538065A JP2023511903A JP2023511903A JP2023538065A JP 2023538065 A JP2023538065 A JP 2023538065A JP 2023511903 A JP2023511903 A JP 2023511903A JP 2023511903 A JP2023511903 A JP 2023511903A JP 2023538065 A JP2023538065 A JP 2023538065A
Authority
JP
Japan
Prior art keywords
compound
subject
cholesterol
per day
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023511903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538065A5 (https=
Inventor
ベラチュー，シベシー
カヒルマクファーランド，エレン
シャオ，チャオフイ
ツァイ，フイ－シン
ウェイ，ルー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2023538065A publication Critical patent/JP2023538065A/ja
Publication of JP2023538065A5 publication Critical patent/JP2023538065A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
JP2023511903A 2020-08-19 2021-08-19 多発性硬化症の寛解を処置する方法 Pending JP2023538065A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063067727P 2020-08-19 2020-08-19
US63/067,727 2020-08-19
PCT/US2021/046589 WO2022040369A1 (en) 2020-08-19 2021-08-19 Methods for treating remitting multiple sclerosis

Publications (2)

Publication Number Publication Date
JP2023538065A true JP2023538065A (ja) 2023-09-06
JP2023538065A5 JP2023538065A5 (https=) 2024-08-23

Family

ID=77693630

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023511903A Pending JP2023538065A (ja) 2020-08-19 2021-08-19 多発性硬化症の寛解を処置する方法

Country Status (6)

Country Link
US (1) US20230390270A1 (https=)
EP (1) EP4199927A1 (https=)
JP (1) JP2023538065A (https=)
CN (1) CN116096421A (https=)
TW (1) TW202227069A (https=)
WO (1) WO2022040369A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472171B2 (en) * 2020-08-19 2025-11-18 Biogen Ma Inc. Methods for treating hypercholesterolemia
WO2023154925A1 (en) * 2022-02-14 2023-08-17 Genetic Innovations, Inc. Medical spectroscopy and imaging analysis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518541A (ja) * 2011-02-07 2014-07-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓ１ｐ調節薬
JP2015528811A (ja) * 2012-07-27 2015-10-01 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｓ１ｐ調節剤および／またはａｔｘ調節剤である化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2899322A1 (en) * 2013-01-29 2014-08-07 Biogen Ma Inc. S1p modulating agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518541A (ja) * 2011-02-07 2014-07-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓ１ｐ調節薬
JP2015528811A (ja) * 2012-07-27 2015-10-01 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｓ１ｐ調節剤および／またはａｔｘ調節剤である化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOMOL. CONCEPTS, vol. 5, no. 4, JPN6025030038, 2014, pages 289 - 298, ISSN: 0005648417 *

Also Published As

Publication number Publication date
WO2022040369A8 (en) 2022-04-14
US20230390270A1 (en) 2023-12-07
WO2022040369A1 (en) 2022-02-24
CN116096421A (zh) 2023-05-09
EP4199927A1 (en) 2023-06-28
TW202227069A (zh) 2022-07-16

Similar Documents

Publication Publication Date Title
JP7734427B2 (ja) 神経由来エクソソーム中の核酸の検出方法および分析方法
US12219938B2 (en) Mouse model of alcohol-induced liver cancer
EP3080602B1 (en) Treating neurodegenerative disease
TW201932109A (zh) 治療肝臟疾病之方法
US20240299457A1 (en) Methods for treating disease associated with senescence
JP2023538065A (ja) 多発性硬化症の寛解を処置する方法
Zhu et al. Repurposing of omeprazole for oligodendrocyte differentiation and remyelination
EP4440571A1 (en) Prevention and treatment of depressive disorders and conditions promoted by protease containing plasma extracellular vesicles (pcpev)
JP7824930B2 (ja) 高コレステロール血症の治療方法
US8709997B2 (en) Prevention and treatment of osteoarthritis
JP2019524805A (ja) 髄鞘再生療法
EP3831369A1 (en) Squalene for the treatment of demyelinating disorders
Maimaiti et al. Neuron-specific Mafb knockout causes growth retardation accompanied by an impaired growth hormone/insulin-like growth factor I axis
EP2145193A1 (en) Methods and compositions for upregulation of gata activity
EP4407315A1 (en) Diagnosis and treatment of neurogenic heterotopic ossification
Kamel et al. STUDIES ON ADIPOSE–DERIVED STEM CELLS AS TREATMENT OF MUSCULAR DYSTROPHY INDUCED IN RATS
WO2026056743A1 (zh) 鉴定对象或其组织或器官的衰老程度和评估衰老干预效果的方法
WO2023079079A1 (en) Methods for treating multiple sclerosis
WO2023228701A1 (ja) 中枢性脱髄疾患の予防剤、病態進行抑制剤、又は治療剤
JP2020513232A (ja) 糖代謝異常の検出方法と予防及び治療
Provias et al. brain pathology brain pathology
CN121489954A (zh) Ogg1小分子激动剂在制备用于治疗肝脏炎症性疾病的药物中的应用
English Alterations in the myogenic capacity of satellite cells in a mouse model of ALS
Shavlakadze et al. GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration
Murakami et al. P. 8.4 Steroid Treatment for exacerbation of muscle weakness after viral infection in Fukuyama congenital muscular dystrophy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240815

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260130